抗癫痫药与抗生素相互作用:系统综述与荟萃分析及给药启示
该系统综述与荟萃分析评估抗癫痫药与抗生素的药代动力学相互作用,纳入截至2017年6月9日的报告。荟萃分析显示大环内酯类升高卡马西平AUC∞和谷浓度并降低清除率,碳青霉烯类显著降低丙戊酸谷浓度。建议长期抗癫痫治疗患者进行TDM以改善安全性并保持疗效。
要点
- 大环内酯类使卡马西平AUC∞增加34.5 µg/mL*h(p=0.005,n=38)。
- 碳青霉烯类使丙戊酸谷浓度降低42.9 µg/mL(p<0.001,n=262)。
- 长期抗癫痫治疗患者可考虑TDM以优化安全性和疗效。
核心结论
- 大环内酯类与卡马西平存在显著药代动力学相互作用,碳青霉烯类显著降低丙戊酸谷浓度。
- 特定情况下对长期抗癫痫治疗患者进行TDM可能有助于改善安全性并保持疗效。
研究设计与样本
- 系统综述与荟萃分析,检索截至2017年6月9日发表的抗癫痫药与抗生素药代动力学相互作用报告。
主要发现
- 大环内酯类使卡马西平AUC∞增加34.5 µg/mL*h(p=0.005,n=38)。
- 大环内酯类使卡马西平清除率降低2.88 mL/min(p<0.001,n=46)。
- 大环内酯类使卡马西平谷血浆浓度增加8.0 µg/mL(p=0.002,n=23)。
- 碳青霉烯类使丙戊酸谷浓度降低42.9 µg/mL(p<0.001,n=262)。
关键数值与推荐
- 大环内酯类与卡马西平:AUC∞ +34.5 µg/mL*h(p=0.005,n=38),清除率-2.88 mL/min(p<0.001,n=46),Ct +8.0 µg/mL(p=0.002,n=23)。
- 碳青霉烯类与丙戊酸:Ct -42.9 µg/mL(p<0.001,n=262)。
临床怎么用
- 长期抗癫痫治疗患者合并使用大环内酯类或碳青霉烯类时,可考虑进行治疗药物监测以评估药代动力学变化。
- TDM有助于在特定条件下改善安全性并保持疗效。
局限性
- 其他抗癫痫药-抗生素相互作用的药代动力学参数报告不足,无法进行统计分析。
- 部分相互作用现有信息提示有相关效应但尚不足以得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Qualitative studies on drug-drug interactions (DDIs) between anticonvulsants and antibiotics report pharmacokinetic changes that may increase the clinical risks in terms of adverse drug reactions (ADRs) and efficacy. However, no studies have provided a systematic and quantitative analysis of anticonvulsant-antibiotic pharmacokinetic DDIs. To provide such indications, we systematically and critically reviewed the literature on anticonvulsant-antibiotic DDIs in terms of quantitative pharmacokinetic changes and related ADRs. We also investigated less-known interactions for the possible occurrence of clinically relevant events. METHODS: We conducted a systematic review of all reports of DDIs between anticonvulsants and antibiotics assessing pharmacokinetic parameters published until 9 June 2017. RESULTS: We were able to meta-analyse the effect of macrolides on carbamazepine area under the concentration-time curve from time zero to infinity [AUC∞] (+ 34.5 µg/mL*h, p = 0.005, n = 38), clearance (- 2.88 mL/min, p < 0.001, n = 46) and trough plasma concentration [Ct] (+ 8.0 µg/mL, p = 0.002, n = 23), and of carbapenems on valproic acid Ct (- 42.9 µg/mL, p < 0.001, n = 262). Pharmacokinetic parameters with other DDIs were insufficiently reported to allow a statistical analysis. CONCLUSIONS: Therapeutic drug monitoring in patients receiving long-term antiepileptic therapies may help, in specific conditions, to improve safety while preserving efficacy. Such a procedure would also increase scientific information on how pharmacokinetic variations are associated with ADR occurrence, and possibly epileptological outcomes for those DDIs for which available information is suggestive of a relevant effect but is not yet sufficient to draw conclusions.
引用
- Carnovale C, Pozzi M, Mazhar F, et al. Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications. Clin Pharmacokinet. 2019. PMID: 30406474. doi:10.1007/s40262-018-0720-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。